Synthetic immunology

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, October 27, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Stomach, TAC, GPC3, Society, GUCY2C, Society for Immunotherapy of Cancer, Annual general meeting, Presentation Public School, News, Immunotherapy, Journal, Technology, EST, Patient, Lonza, Cancer, IND, SITC, Synthetic immunology, 2021 Essex County Council election, JITC, Therapy, Safety, Vaccine

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually.
  • Full abstract content will be available online in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7, 2022 at 8:00 a.m. EST.
  • Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology.
  • Triumviras pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years.

Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer

Retrieved on: 
Tuesday, October 25, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, GPC3, Boston Consulting Group, Therapy, Sale, Growth, IND, Business administration, IPO, Patient, Business, Multimedia, DoubleTwist, Cancer, Technology, Synthetic immunology, Safety, Federal Reserve Board of Governors, GUCY2C, Lonza, TAC, Master of Business Administration, Leadership, Pharmaceutical industry, Management, Economics, Cain (band), Pomona College

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced the appointment of Robert Williamson as President and Chief Business Officer.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced the appointment of Robert Williamson as President and Chief Business Officer.
  • Mr. Williamson will lead business development and strategy for Triumvira, and will work within Triumviras leadership team to establish new value-creating partnerships, drive long-term strategic plans, and advance fundraising activities.
  • View the full release here: https://www.businesswire.com/news/home/20221024006042/en/
    Robert Williamson, President and Chief Business Officer of Triumvira (Photo: Triumvira)
    Mr. Williamson brings more than 25 years of experience in the biotechnology sector, leading company business development and financing efforts through partnerships, private funding and public capital markets.
  • Prior to joining Triumvira, Mr. Williamson was President and Chief Executive Officer at BioTheryX, Inc.

Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Health, FDA, Clinical Trials, Research, Science, Biotechnology, Stomach, GPC3, Therapy, IND, GMP, Patient, Research, C3I, Cancer, Technology, Synthetic immunology, CEO, Safety, GUCY2C, Lonza, FDA, TAC, Pharmaceutical industry, Vaccine, Cain (band)

The advanced research and manufacturing space features an FDA-compliant GMP facility and will be staffed by Triumvira technical operations experts in cell therapy manufacturing, with plans for additional personnel in the coming years.

Key Points: 
  • The advanced research and manufacturing space features an FDA-compliant GMP facility and will be staffed by Triumvira technical operations experts in cell therapy manufacturing, with plans for additional personnel in the coming years.
  • The South San Francisco facility is Triumviras second manufacturing location and is expected to provide supplemental manufacturing capacity to meet the demand for its ongoing clinical research studies.
  • Once operational, the South San Francisco facility will manufacture TAC01-HER2, which is currently in a Phase 1/2 trial for solid tumors, and manufacture additional candidates for subsequent clinical studies.
  • Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology.

Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022

Retrieved on: 
Wednesday, October 12, 2022
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, GPC3, Therapy, Conference, IND, Patient, Bank, Privately held company, Technology, Synthetic immunology, Cain (band), Safety, Senior management, GUCY2C, Lonza, Next wave, TAC, Pharmaceutical industry

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences.
  • Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date.
  • Triumviras pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years.
  • Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Technology, New Resource Bank, Abstract (summary), News, TAC, Synthetic immunology, European Society for Medical Oncology, EDT, ESMO, Presentation Public School, Congress, HER2, Paris Expo Porte de Versailles, Therapy, Oncology, CEST, TCR, Patient, Vaccine

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).

Key Points: 
  • TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
  • Location: Paris Expo Porte de Versailles, Hall 4
    Abstracts will be published online on the ESMO website at 12:05 a.m. CEST on Sept. 5, 2022 (6:05 p.m. EDT on Sept. 4, 2022).
  • Triumvira Immunologics, Inc. (Triumvira) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.
  • The companys proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies.

Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million

Retrieved on: 
Thursday, March 17, 2022
Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Oncology, MBA, TCR, Multiple myeloma, Research, Gaps, Technology, Health care, Patient, Breast, Therapy, General partnership, Safety, TAC, Synthetic immunology, Bayer, Neoplasm, CEO, Capital Group Companies, Growth, Precision medicine, Vaccine, Cain (band)

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million.
  • The proceeds of the financing will support the continued preclinical and clinical development of Triumviras T cell Antigen Coupler (TAC)-T cell therapy programs.
  • Triumviras proprietary TAC receptor, a multi-domain chimeric molecule, interacts directly with the natural T cell receptor to uniquely help T cells recognize and eliminate tumor cells.
  • Cell therapies have become an essential modality in the oncology therapeutic arsenal and a priority for many biopharma companies.

Triumvira Immunologics Establishes Scientific Advisory Board

Retrieved on: 
Tuesday, January 18, 2022
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Coronavirus Scientific Advisory Board (Turkey), TAC, Research, Genetic engineering, Molecular Therapy, Patient, Pathology, Technology, Haematopoietic system, Degenerative disease, Clinical trial, University, Baylor College of Medicine, Division, International Society, Gene therapy, Cell, Pediatrics, CEO, Gene, Society, Center, Department of Medicine – University of Pamplona, Industry, Center for Cell and Gene Therapy, Fox Chase Cancer Center, Synthetic immunology, Hospital, ISCT, MD Anderson Cancer Center, McKesson Corporation, Drug development, Therapy, Inflammation, SAB, Cancer, Neoplasm, McMaster University, Translational research, Massachusetts General Hospital, TCR, Baylor University, American Society of Gene and Cell Therapy, Physician, Pharmaceutical industry, Management, Vaccine, Cain (band), Molecular medicine, Medicine

Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.

Key Points: 
  • Triumvira Immunologics (Triumvira), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.
  • Having recently dosed the first patient in a clinical trial of TAC01-HER2, our clinical program is at an exciting inflection point and I believe that each member of our Scientific Advisory Board will serve Triumvira well as we strive to deliver new treatments to patients with difficult-to-treat cancers.
  • Im honored to serve as chair of Triumviras Scientific Advisory Board alongside distinguished experts in our industry, said Dr. Bramson.
  • The founding members of the Triumvira Scientific Advisory Board are:
    Dr. Bramson is the founder of Triumvira and chair of its Scientific Advisory Board.

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Pharmaceutical, Health, Associate, ETH Zurich, Technology, Learning, Drug discovery, Engineering, System, Patient, Therapy, ATX, ML, Machine learning, Antibody, Department, Synthetic immunology, AI, Fine chemical

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization.
  • The team and technology stack will form new bioinformatics and machine learning (ML) capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes.
  • The ongoing technology improvements will enhance the output of Alloy platforms and Alloy Discovery Services for the benefit of all of our drug discovery partners.
  • DeepCDRs technology will strengthen Alloy Discovery Services capabilities with patent-pending machine learning-powered antibody repertoire screening, in silico library screening, and mammalian display.

Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial

Retrieved on: 
Monday, September 20, 2021
Health, Stem Cells, Clinical Trials, Other Health, Cancer, Breast, Clinical trial, HER2, Platform, MD Anderson Cancer Center, Therapy, Synthetic immunology, Patient, Dana–Farber Cancer Institute, Population, Chimeric antigen receptor T cell, Lymphatic system, CEO, University, Program, Cocoon, TCR, TAC, Technology, Safety, University of Chicago, Vaccine, Pharmaceutical industry

Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors.

Key Points: 
  • Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors.
  • The companys proprietary T cell Antigen Coupler (TAC) platform technology activates natural T cell functions differently from other cell therapies such as Chimeric Antigen Receptor T cell (CAR-T) and engineered T cell receptor therapies.
  • The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology.
  • With this trial, Triumvira is the first company in the U.S. to dose a patient with a therapy manufactured with Lonzas Cocoon Platform.

GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies

Retrieved on: 
Wednesday, October 28, 2020
Life sciences, Branches of biology, Health sciences, Cell biology, Stem cells, Immunology, Biotechnology, Cell therapy, Synthetic immunology, Therapy

Additionally, GentiBio expanded its existing partnership with MIGAL Galilee Research Institute to further leverage the institute's expertise in synthetic immunology.

Key Points: 
  • Additionally, GentiBio expanded its existing partnership with MIGAL Galilee Research Institute to further leverage the institute's expertise in synthetic immunology.
  • Adding their leadership to GentiBio will be critical in helping us achieve our business and scientific goals."
  • "Enabling durable cell therapy engraftment in immune competent patients will advance the reach of EngTregs and cell therapy platforms, positioning GentiBio to become a leader in allogeneic cell therapy," said Nada.
  • Recognized as a powerhouse of applied research, for forty years MIGAL has cooperated closely with industry leaders, innovative startups, and technological accelerators.